Copyright
©The Author(s) 2022.
World J Cardiol. Jul 26, 2022; 14(7): 438-445
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.438
Published online Jul 26, 2022. doi: 10.4330/wjc.v14.i7.438
Ref. | Drug | LVEF cut off | |
Registries | |||
Yancy et al[22] | ADHERE | - | ≥ 40 |
Fonarow et al[23] | OPTIMIZE-HF | - | ≥ 40%; ≥ 50% |
Steinberg et al[24] | GWTG-HF | - | ≥ 50%; 40%-50% |
Randomized controlled trials | |||
Yusuf et al[25] | CHARM-PRESERVED | Candesartan | > 40% |
Cleland et al[26] | PEP-CHF | Perindopril | > 40% |
Massie et al[27] | I-PRESERVE | Irbesartan | ≥ 45% |
van Veldhuisen et al[28] | SENIORS | Nebivolol | > 35% |
Redfield et al[29] | RELAX Trial | Phosphodiesterase-5 inhibitors | ≥ 50 |
Yamamoto et al[30] | J-DHF | Carvedilol | > 40% |
Ahmed et al[31] | DIG-PEF | Digitalis | > 45% |
Pitt et al[32] | TOPCAT | Spironolactone | ≥ 45% |
Solomon et al[33] | PARAMOUNT | Sacubitril/Valsartan | ≥ 45% |
Solomon et al[34] | PARAGON HF | Sacubitril/Valsartan | ≥ 45% |
Pieske et al[35] | SOCRATES-PRESERVED | Vericiguat | ≥ 45% |
Armstrong et al[36] | VITALITY-HFpEF | Vericiguat | ≥ 45% |
Anker et al[15] | EMPEROR-PRESERVED | Empagliflozin | > 40% |
Solomon et al[37] | DELIVER trial | Dapagliflozin | > 40% |
Meta-analysis | |||
Meta-analysis Global Group in Chronic Heart Failure[38] | MAGGIC | - | ≥ 50 |
Zheng et al[39] | Systematic review and meta-analysis | Neurohormonal inhibitors | ≥ 40% |
- Citation: Xanthopoulos A, Giamouzis G, Skoularigis J, Triposkiadis F. Heart failure with reduced, mildly reduced, or preserved left ventricular ejection fraction: Has reasoning been lost? World J Cardiol 2022; 14(7): 438-445
- URL: https://www.wjgnet.com/1949-8462/full/v14/i7/438.htm
- DOI: https://dx.doi.org/10.4330/wjc.v14.i7.438